The Society for Immunotherapy of Cancer (SITC) Cancer Immunotherapy Guidelines are a collection of consensus statements developed by experts to help oncologists determine when and how to best use immunotherapy to treat their patients. The guidelines are developed using a systematic process to ensure the recommendations are unbiased, relevant, and facilitate clinical decision-making. The guidelines will be evaluated and updated on an ongoing basis.
Prior to publication of each guideline, a Member Comment period is launched to allow SITC members to review a draft copy of the guideline and provide feedback, with the goal of further improving the draft. Click here to learn more about the Member Comment period.
In response to the ever-growing demand for expert guidance on the optimal use of immunotherapy treatments, our Cancer Immunotherapy Guidelines committees have developed consensus statements for cutaneous melanoma, genitourinary malignancies (renal, prostate and bladder carcinoma) and hematologic malignancies (multiple myeloma, lymphoma and acute leukemia).
New guidelines for non-small cell lung cancer and head and neck cancers are currently underway. These disease-specific Cancer Immunotherapy Guidelines offer a vital resource for the practicing oncology community.